-
Nov 7, 2024 | 
radcliffecvrm.com | Andrew Coats |Brad H Rovin |Jürgen Floege |Muthiah Vaduganathan
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease. In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).
-
Dec 20, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. In this discussion, Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD anticipate the imminent release of phase three data for drugs targeting the BAFF (B-cell activating factor) and APRIL (A proliferation-inducing ligand) axis, particularly April only and April and BAFF approaches.
-
Dec 20, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the latest data on drugs targeting the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) axis in IgA nephropathy (IgAN), presented at the American Society of Nephrology (ASN) meeting.
-
Dec 13, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the modulation of B cells, specifically targeting cytokines Baff and April, crucial for IgA class switch recombination. Dr Rovin draws on his experience in lupus nephritis, where the Baff inhibitor Belimumab showed efficacy in inducing renal responses and preserving kidney function.
-
Dec 13, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. The discussion shifts to the emerging class of drugs targeting the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) axis in IgA nephropathy (IgAN).
-
Dec 6, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. In this discussion between Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, the focus shifts to the emerging therapeutic options for IgA nephropathy (IgAN).
-
Dec 6, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. In the discussion between Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, they explore the challenges and potential therapeutic approaches for IgA nephropathy (IgAN). Dr Rovin begins by acknowledging the limitations of current treatments that primarily address the consequences of kidney damage rather than the underlying causes.
-
Nov 29, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. In this transcript, Dr Brad Rovin discusses the pathogenic cascade of IGA nephropathy and highlights multiple intervention points for clinicians. Emphasizing the significance of understanding how these points interact, he underscores the importance of combining therapies to achieve desired outcomes.
-
Nov 29, 2023 | 
hcplive.com | Jonathan Barratt |Brad H Rovin
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD. Two nephropathy experts discuss advancements in immune modulating therapies for IgA nephropathy (immunoglobulin A). Dr Rovin outlines the pathogenic drivers for kidney function loss in IgA, emphasizing four hits to the kidney: overproduction of galactose-deficient IgA, deposition in glomeruli, inflammatory processes, and subsequent kidney damage.
-
Nov 13, 2023 | 
healio.com | Jason Laday |Shenaz Bagha |Brad H Rovin
You've successfully added Rheumatology: Lupus to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
